SwitzerlandSwitzerland

Leukemia - BMS drug more effective than Novartis' Glivec

07.06.2010

Basel/Chicago/Princeton - Preliminay data from a Phase III study show that BistolMyers Squibb's (BMS) BCR-ABL kinase inhibitor dasatinib (Sprycel) is superior to Swiss Novartis' standard first-line therapy, imatinib (Glivec), for bringing about cytogenetic and molecular responses in patients newly diagnosed with chronic myeloid leukemia (CML). According to results presented at the ASCO meeting in Chicago, 73% of blood cancers did not progress after 3 years of treatment with Sprycel and 87% of CML patients, who do not respond to imatinib, survived. In a head-to-head comparison with Glivec, Sprycel seemed to be more effective. 77% of the patients treated with the BMS drug showed the complete disappearance of cells with the Philadelphia chromosome, a surrogate marker for long-term survival of CML patients, compared to 66% of patients treated with Glivec after 12 months of treatment. Additionally, the rate of major molecular responses – another marker of drug effectiveness – was also higher with dasatinib (46%) than imatinib (28%). Both drugs showed similar side effects such as Grade 3/4 anemia (10% vs 7%) and neutropenia (21% vs 20%). However, thrombocytopenia was more common for dasatinib (19% vs 10%). In a separate press statement, Novartis announced that 18-month results from a study confirmed its nilotinib (Tasigna) cancer drug is more efficient in slowing down CLM than older medicine Glivec, its second-biggest selling drug. The results will be also presented at the ASCO meeting.

SwitzerlandSwitzerland

30.03.2012

Basel/Hinxton (UK) – Two European teams have created huge repositories of cancer genomics data that help predict drug response. Swiss Novartis and the Boston-based Broad Institute have combined data obtained from large-scale...

SwitzerlandSwitzerland

27.03.2012

London/Lausanne – The global private equity firm Celtic Therapeutic L.L.L.P. believes in the power of antibody-drug conjugates (ADCs). It is investing $50m in a new Switzerland-based company called ADC Therapeutics Sarl which...

SwitzerlandSwitzerland

26.03.2012

Basel/Vienna - Following promising results from a Phase III study, Roche has submitted a regulatory application to EMA for subcutaneous Herceptin (trastuzumab) to treat HER2-positive breast cancer. Roche said subcutaneous...

SwitzerlandSwitzerland

09.03.2012

After the US Food & Drug Administration forced Swiss generics giant Sandoz AG to update its production facilities in Quebec, there are now fears that supplies of some medicines could grow tight in Canada. The regulatory authority...

SwitzerlandSwitzerland

08.03.2012

The hepatitis C space has seen a string of large deals in the last weeks that include a US$11bn buyout of Pharmasset by Gilead. Now Novartis is also trying to get in the game with the purchase of a global exclusive licence from...

SwitzerlandSwitzerland

06.03.2012

Allschwil – Swiss Actelion Ltd. has strengthened its commercial offerings by securing rights in certain countries to Auxilium’s biotech drug Xiaflex for treating tissue buildup under the skin. The US pharma is to receive US$10m...

SwitzerlandSwitzerland

06.03.2012

Zug – Life Sciences specialist HBM partners has raised €90m in the first close of its HBM BioCapital II fund, which will invest in revenue-generating companies in the pharmaceuticals, medical device and diagnostics sectors....

SwitzerlandSwitzerland

05.03.2012

Stans – Mondobiotech, a drug discovery company in troubled waters, could soon be under Italian ownership: The Swiss biotech announced it has entered into exclusive negotiations with Milan-based provider of pharmaceutical and...

Displaying results 1 to 10 out of 276

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-switzerland/article/leukemia-bms-drug-more-effective-than-novartis-glivec.html

Events

All Events

Stock list

All quotes

TOP

  • CO.DON3.13 EUR5.03%
  • 4SC1.06 EUR3.92%
  • SANTHERA88.65 CHF2.78%

FLOP

  • CYTOS0.19 CHF-9.52%
  • WILEX2.13 EUR-6.99%
  • FORMYCON8.03 EUR-5.42%

TOP

  • PAION3.18 EUR33.6%
  • CO.DON3.13 EUR27.8%
  • FORMYCON8.03 EUR14.2%

FLOP

  • CYTOS0.19 CHF-26.9%
  • ADDEX3.13 CHF-18.1%
  • EVOTEC3.06 EUR-16.8%

TOP

  • SANTHERA88.65 CHF2155.7%
  • PAION3.18 EUR224.5%
  • CO.DON3.13 EUR222.7%

FLOP

  • CYTOS0.19 CHF-95.2%
  • 4SC1.06 EUR-43.9%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 30.09.2014


Current issue

All issues

Product of the week

Products